Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs | ||
By: GlobeNewswire - 03 Oct 2022 | Back to overview list |
|
NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Paul McInulty has joined the company as Senior Vice President, Regulatory Affairs. “We are delighted to welcome Paul to our leadership team in this crucial role as we enter the next phase of Arvinas – a late-stage development company,” said John Houston, Ph.D., Arvinas President and Chief Executive Officer. “Paul’s vast experience leading global and regional development programs from discovery through commercialization in a wide range of therapeutic areas and modalities will be very valuable as Arvinas continues on an incredible growth trajectory.” “I am excited to join Arvinas and to be part of the company that is truly leading the way in the targeted protein degradation industry through its validated PROTAC® protein degradation platform,” said Mr. McInulty. “As Arvinas transitions into a late-stage development company, I look forward to supporting the organization on this journey and the opportunity to contribute my experience in leading global regulatory strategies.” About Arvinas Forward-Looking Statements We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to:, whether we will be able to successfully conduct and complete clinical development of our product candidates, including whether we initiate and receive results from our clinical trials on our expected timelines or at all, obtain marketing approval for and commercialize our product candidates on our current timelines or at all and other important factors discussed in the “Risk Factors” sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release. Contacts Media:
|
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |